(Q38218566)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Mauro Viganò

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Giampaolo Mangia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

1019-1031

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

A review of the current use of rituximab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Rituximab-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fatal reactivation of hepatitis B after chemotherapy for lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Urgent liver transplantation for chemotherapy-induced HBV reactivation: a suitable option in patients recently treated for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

Occult hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.912273

10.1517/14712598.2014.912273

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24909454%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference